Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.
Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.
VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.
Inhibition of hepatic PCSK9 synthesis with the small interfering RNA inclisiran led to significant reductions of non-HDL-c and apoB, and increases of HDL-c, which were sustained up to day 180.
BNP is a strong predictor of all-cause death in patients with and without HF, and the risk of death associated with elevated BNP levels is similar between patients with and those without HF.
Electric and magnetic fields generated during operation and charging of electric cars did not affect the function or programming of cardiac implantable electronic devices.
In a retrospective analysis of a healthcare cost and utilization database, cannabis use was associated with a lower AF risk in hospitalized heart failure patients.
24-hour, daytime, and nighttime ambulatory systolic blood pressure measurements were better predictors of all-cause and CV mortality compared with blood pressure measurements in the clinic.
To what extent does bleeding on VKA differ from on DOAC treatment? Menno Huisman and Alexander Cohen discuss the management and outcomes of bleeding on direct oral coagulation therapy.
FDA has approved andexanet alfa, to reverse anticoagulation induced by rivaroxaban or apixaban, in case of life-threatening or uncontrolled bleeding